2018
Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone
Young LH, Viscoli CM, Schwartz GG, Inzucchi SE, Curtis JP, Gorman MJ, Furie KL, Conwit R, Spatz E, Lovejoy A, Abbott JD, Jacoby DL, Kolansky DM, Ling FS, Pfau SE, Kernan WN. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. Circulation 2018, 138: 1210-1220. PMID: 29934374, PMCID: PMC6202153, DOI: 10.1161/circulationaha.118.034763.Peer-Reviewed Original ResearchConceptsRisk of HFTransient ischemic attackEffect of pioglitazoneHF riskHeart failureInsulin-resistant patientsMyocardial infarctionIschemic attackCardiovascular benefitsIschemic strokeDiabetes mellitusInsulin resistanceHigher C-reactive proteinComposite of strokeHF risk scoreHigher HF riskDrug dose reductionHospitalized heart failureIncident myocardial infarctionLower mean doseC-reactive proteinBaseline patient featuresHF hospitalizationCardiovascular eventsPlacebo groupWhat Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial?
INZUCCHI S, VISCOLI C, YOUNG L, GORMAN M, CONWIT R, SCHWARTZ G, KERNAN W. What Mediated Pioglitazone's Cardiovascular (CV) Benefit in the IRIS Trial? Diabetes 2018, 67 DOI: 10.2337/db18-17-lb.Peer-Reviewed Original ResearchTransient ischemic attackDensity lipoprotein cholesterolInsulin resistanceCV benefitsLog HRCardiovascular benefitsLipoprotein cholesterolBlood pressureStroke/transient ischemic attackHigh-sensitivity C-reactive proteinHigh-density lipoprotein cholesterolLow-density lipoprotein cholesterolMeasures of IRInsulin Resistance InterventionHomeostatic model assessmentDiastolic blood pressureEffect of pioglitazoneSystolic blood pressureC-reactive proteinFavorable effectBoehringer Ingelheim PharmaceuticalsPIO effectIschemic attackNondiabetic patientsHOMA-IR
2004
Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics–Brachial Artery Reactivity study)
Papaioannou GI, Seip RL, Grey NJ, Katten D, Taylor A, Inzucchi SE, Young LH, Chyun DA, Davey JA, Wackers FJ, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Engel S, Heller GV. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics–Brachial Artery Reactivity study). The American Journal Of Cardiology 2004, 94: 294-299. PMID: 15276091, DOI: 10.1016/j.amjcard.2004.04.022.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAlbuminuriaBrachial ArteryCoronary Artery DiseaseC-Reactive ProteinDiabetes Mellitus, Type 2Diabetic AngiopathiesEndothelium, VascularFemaleHumansLinear ModelsMaleMiddle AgedMultivariate AnalysisProspective StudiesReference ValuesRisk AssessmentSensitivity and SpecificitySeverity of Illness IndexSex FactorsUltrasonography, DopplerVasoconstrictionVasodilationConceptsEndothelium-independent vasodilationEndothelium-dependent vasodilationBrachial artery reactivityType 2 diabetes mellitusHormone replacement therapyDiabetes mellitusC-reactive proteinSystemic inflammationAsymptomatic patientsEndothelial dysfunctionIndependent predictorsReplacement therapyNovel atherosclerotic risk factorAsymptomatic Diabetics (DIAD) studyAtherosclerotic risk factorsPresence of microalbuminuriaFuture cardiovascular eventsSimilar baseline characteristicsDetection of ischemiaCardiovascular eventsBaseline characteristicsBrachial arteryVascular dysfunctionEntire cohortRisk factors